The global red biotechnology market was valued at USD 515.58 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 10.6% from 2023 to 2030. The increasing demand for personalized medicine, high investment in R&D of biotechnology products, and the rising advances in genetic research. Red biotechnology deals with biotechnological applications such as stem cells, gene therapy, genetic engineering, and the development of new drugs and vaccines. Red biotechnology is a process that uses organisms to improve health care and aid the body in disease-fighting. It is a subset of modern technology used in the field of medicine. Red biotechnology is applicable not only to the pharmaceutical industry but also to the medical sector, as it aids in the alleviation of human suffering and improves the quality of life. The rising usage of genetic engineering to produce biological medicine is one of the major trends. This includes using recombinant DNA technology to create genetically modified organisms capable of producing large amounts of a specific protein, such as a therapeutic antibody.
The market is expected to witness lucrative growth during the forecast period. The market has made significant advances in disease control, from antibiotics for treating acute microbial infections to chronic conditions such as anti-HIV/AIDS. One of which being azidothymidine which has helped managing AIDS.
Many pharmaceutical companies are developing and manufacturing pipeline products for diabetes and neurological disorders such as Alzheimer's and Parkinson's disease. According to the clinicaltrials.gov, there were 126 agents in clinical trials for the treatment of Alzheimer's disease as of January 2021, with 28 treatments in phase III trials. Fermentation technology is being widely used in the life sciences and healthcare sectors, which is positively impacting market growth.
The market is still a growing field with enormous potential for driving medical advancements and transforming the identification of diseases caused by genetic factors. Novel tests can detect changes in the DNA sequence of genes linked to disease risk. Early detection is frequently the crucial factor in avoiding disease or slowing disease progression through early treatment.
The pandemic of COVID-19 has had a significant impact on the red biotechnology market. The biotechnology industry has always relied heavily on innovation. Even in the presence of the COVID-19 pandemic, significant progress is being made in the discovery and development of novel drugs. Despite the numerous challenges posed by the pandemic, the key growth drivers for red biotechnology have remained intact, and the industry will continue to generate innovative new drugs in both the short and long term.
Furthermore, as a result of the COVID-19 pandemic, drug developers are facing some new operational challenges, and anticipate some influence on clinical trial timelines as well as the number of new drug approvals in the future. The market players that are actively running clinical trials for investigational drugs are experiencing a slowdown in patient enrollment and have been forced to temporarily close trial sites entirely, as hospitals prioritize COVID-19 patients' treatment. The pipeline of COVID-19 drugs and vaccines is growing at an unprecedented rate and will be effective in treating and preventing infections.
Monoclonal antibodies held the major share of the red biotechnology market with 43.1% in 2022. The rising prevalence of chronic diseases such as cardiovascular disease, cancer, etc. is increasing the demand for biologics, which is expected to serve as a key factor driving the segment's growth. Furthermore, the COVID-19 pandemic has fueled the development of several mAbs directed against the SARS-CoV-2 virus, which has increased market expansion prospects. The mAbs are a promising alternative for COVID-19 mitigation due to their safety and effectiveness, several of these antibodies have received emergency use authorizations from the U.S. FDA.
Gene therapy products are likely to witness the fastest growth in the market. It is expected to expand at a CAGR of 24.3% between 2023 and 2030. The growth can be attributed to factors such as the expansion of gene delivery technologies and advanced therapies, as well as the development of progressive competition among major market players focused on the commercialization of their therapies. According to the American Society of Gene & Cell Therapy (ASGCT), approximately 1,986 gene therapy products are in development, including genetically modified cell therapies and CAR T-cell therapies.
Pharmaceutical & biotechnology companies are expected to account for the largest market share in 2022. The segment contributed 45.6% of revenues in 2022. Pharmaceutical and biotechnology companies are dealing with a variety of challenging trends. The global demand for COVID-19 vaccines and therapeutics is increasing rapidly, placing an added burden on the industry. The company's ability to find an innovative way to provide COVID-19 vaccines while still meeting overall demand is remarkable, but rising global demand remains a significant long-term challenge for the industry. These businesses are experiencing a wave of innovation, from new treatment modalities to advanced analytics, smart machines, and digital connectivity.
CMOs & CROs is the fastest-growing sub-segment. It is expected to expand at a CAGR of 12.8% between 2023 and 2030. The increasing investment in the biotechnology industry by prominent players to enhance their efficiency and productivity has driven biopharmaceutical manufacturers to increase their focus on outsourcing services. Mergers and acquisitions allow CMOs to offer inclusive bioprocessing services, making CMOs/CROs a feasible option for rapid product launches. The market for CMOs and CROs is still in its early stages, but the introduction of novel therapeutics, new bioprocessing tools, and product priority shifts in the bio/pharmaceutical industry has increased the pressure on contract bio manufacturers.
North America accounted for the largest share of 38.07% in the market in 2022. The large share is mainly attributed to an increase in R&D activities and technological advancements in the field of biotechnology. The U.S. is among the key markets in the biotechnology industry. Major factors such as developed infrastructure, and the rise in the incidence of various diseases are driving the market growth in the region. For instance, In June 2022, a gene therapy developed by Bluebird Bio received support from advisors and is currently being evaluated by the U.S. FDA for the treatment of cerebral adrenoleukodystrophy in patients under the age of 18.
Asia Pacific will likely emerge as the fastest region during the study period. The emerging economies of Asia Pacific countries such as India, and China are majorly contributing to the growth of this region. These countries are involved into private-public collaborations, and government initiatives that are propelling the growth of Asian market.
The increasing demand for red biotechnology for various applications has created numerous market opportunities for the market players to capitalize on. Companies are involved in strategic initiatives such as new product launches, collaborations, and acquisitions to propel their market share. Some of the key players in the global red biotechnology market include:
F. Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Market size value in 2023
USD 492.71 billion
Revenue forecast in 2030
USD 997.74 billion
CAGR of 10.6% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, end-user, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled
Merck KGaA; F. Hoffmann-La Roche AG; Pfizer Inc.; Regeneron Pharmaceuticals; Inc.; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; Gilead Sciences; Biogen Inc.; Amgen Inc.; Celgene Corporation
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented red biotechnology market report based on product, end-user, and region.
Product Outlook (Revenue, USD Billion, 2018 - 2030)
Cell-Based Immunotherapy Products
Gene Therapy Products
Cell Therapy Products
Kits and Reagents
End-User Outlook (Revenue, USD Billion, 2018 - 2030)
Academic Research Institutes
CMOs & CROs
Pharmaceutical & Biotechnology Companies
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
Middle East & Africa
b. The global red biotechnology market size was estimated at USD 515.58 billion in 2022 and is expected to reach USD 492.71 billion in 2023.
b. The global red biotechnology market is expected to grow at a compound annual growth rate of 10.6% from 2023 to 2030 to reach USD 997.74 billion by 2030.
b. North America dominated the red biotechnology market with a share of 38.07% in 2022. This is attributable to rising healthcare awareness and well-established manufacturing facilities of significant players within the U.S.
b. Some key players operating in the red biotechnology market include Merck KGaA,F. Hoffmann-La Roche AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Gilead Sciences, Biogen Inc., Amgen Inc., Celgene Corporation
b. Key factors that are driving the red biotechnology market growth include increasing R&D funding in the biotechnology industry along with technological advances across various platforms
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."